The House of Representatives approved an amendment Wednesday that will facilitate marijuana businesses in working with banking institutions, International Business Times reports. The Heck Amendment, named after its sponsor Rep. Denny Heck (D-WA), was approved by a vote of 231-192. The amendment effectively blocks the SEC and Treasury Department from penalizing banks who lend money to legitimate marijuana businesses in areas where they can legally do business. The Heck Amendment was supported by both parties and represents growing bipartisan support of marijuana businesses, especially after the recent vote by Congress to defund the DEA’s ability to interfere with medical marijuana patients and businesses that are in compliance with state law. If the Heck Amendment is implemented, it will be a major victory in the effort to allow legitimate businesses to control the marijuana market.
In the past, many financial institutions have shied away from assisting marijuana businesses for fear that the federal government will go after them for it, forcing most to operate on a cash-only system. Because of this, they are required to transport thousands of dollars physically, making them targets for robberies and other crimes. Wednesday’s vote is the first step towards allowing legitimate marijuana businesses to utilize alternative forms of payment, such as credit cards and bank accounts, like all other businesses.
As of midnight Wednesday, D.C.’s marijuana decriminalization law is officially in effect. The new law — approved by the D.C. Council, signed by Mayor Gray,
and submitted to Congress for a 60-day review — replaces misdemeanor criminal charges for possession of up to one ounce of marijuana with a civil violation, costing the offender $25. Now D.C. has the third-least punitive marijuana laws in the country, behind Colorado and Washington State.
It is important to note that this is only a change in District law, not federal law. Marijuana possession on federal lands, including the National Mall, is still a criminal offense and violators may be arrested and prosecuted. Public use is still illegal as well. Please see our summary of this new law for more information.
You read that correctly — Congress just voted to end the federal government’s war on medical marijuana!
During a debate regarding a Justice Department funding bill, Rep. Dana Rohrabacher (R-CA), a longtime MPP ally, offered an amendment intended to block DEA raids on medical marijuana dispensaries. It passed by a surprisingly wide margin — 219-189. The amendment will not become law until it is signed by the president, but we’re well on our way.
MPP played a key role in building support for this measure, and we couldn’t have done it without our supporters.
We have had a lot of victories since MPP was founded in 1995, but this is one of the biggest — not just in the organization’s history, but in the history of the marijuana policy reform movement.
We worked with Congressman Rohrabacher and former Congressman Maurice Hinchey on this amendment for more than a decade, and our lobbying presence in Congress has never been stronger. This year alone, we met with staffers from more than 100 congressional offices, as well as dozens of members in person. With this victory, even more doors will be open to us in the future.
U.S. Rep. Steve Cohen (D-TN) introduced a bill Tuesday that would change federal law so that the director of the Office of National Drug Control Policy (ONDCP), commonly known as the “drug czar,” is no longer prohibited from studying the legalization of marijuana and no longer required to oppose attempts to legalize marijuana for medical or broader adult use.
Specifically, H.R. 4046, the Unmuzzle the Drug Czar Act of 2014, would amend the Office of National Drug Control Policy Reauthorization Act of 1998 to remove the following language from the obligations of the director:
(12) shall ensure that no Federal funds appropriated to the Office of National Drug Control Policy shall be expended for any study or contract relating to the legalization (for a medical use or any other use) of a substance listed in schedule I of [the Controlled Substances Act] and.take such actions as necessary to oppose any attempt to legalize the use of a substance (in any form) that –
(A) is listed in schedule I of section 812 of this title; and
(B) has not been approved for use for medical purposes by the Food and Drug Administration;
Rep. Cohen and other members of the House Committee on Oversight and Government Reform slammed the ONDCP during a hearing last week. Rep. Cohen chided the office for failing to address the National Institute on Drug Abuse’s obstruction of research into the medical benefits of marijuana. Rep. Earl Blumenauer (D-OR) criticized it for relying on marijuana “propaganda.” ONDCP Deputy Director Michael Botticelli drew criticism for refusing to acknowledge that marijuana poses less potential harm to the consumer than heroin or methamphetamine.
Members of Congress grilled a representative from the Office of National Drug Control Policy (ONDCP) Tuesday at a hearing of the House Committee on Oversight and Government Reform and slammed the office for failing to acknowledge key facts about marijuana. Rep. Earl Blumenauer (D-OR) chided the drug czar’s office for relying on marijuana “propaganda.” Rep. Steve Cohen (D-TN) criticized the office for failing to address the National Institute on Drug Abuse’s obstruction of research into the medical benefits of marijuana.
During his testimony regarding the Obama administration’s marijuana policy, ONDCP Deputy Director Michael Botticelli refused to acknowledge that marijuana poses less potential harm to the consumer than heroin or methamphetamine.